8-K: Mirum Pharmaceuticals Reports Strong 2024 Financial Results and Provides Business Update

Mirum Pharmaceuticals announces positive 2024 financial results with $336.4 million in net product sales and provides a business update, including 2025 revenue guidance of $420 million to $435 million.

Summary

• Mirum Pharmaceuticals reported its fourth quarter and year-end 2024 financial results and provided a business update on February 26, 2025.
• The company's total net product sales for 2024 reached $336.4 million, compared to $178.9 million in 2023.
• LIVMARLI net product sales totaled $213.3 million in 2024.
• Bile Acid Medicines net product sales totaled $123.1 million in 2024.
• Mirum expects global net product sales of approximately $420 million to $435 million in 2025 and anticipates positive cash flow.
• The VISTAS study of volixibat in PSC is expected to complete enrollment in the second half of 2025, with topline data expected in 2026.
• The VANTAGE study of volixibat in PBC is expected to complete enrollment in 2026.
• The LIVMARLI EXPAND Phase 3 study for pruritus in rare cholestatic conditions is expected to complete enrollment in 2026.
• Mirum plans to initiate a Phase 2 study for MRM-3379 in Fragile X Syndrome (FXS) in 2025.
• Total operating expenses for 2024 were $424.5 million, including $79.4 million of non-cash expenses.
• As of December 31, 2024, Mirum had $292.8 million in cash, cash equivalents, and investments.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial results, revenue growth projections, and pipeline advancements. The company's focus on rare diseases and successful commercialization of its products contribute to a favorable sentiment.

Positives

• Mirum achieved strong revenue growth in 2024, with net product sales reaching $336.4 million.
• The company expects continued revenue growth in 2025, projecting sales between $420 million and $435 million.
• Mirum anticipates positive cash flow in 2025.
• LIVMARLI sales were strong at $213.3 million in 2024.
• The company expanded its global presence with LIVMARLI, reaching 30 countries.
• Volixibat received breakthrough therapy designation for PBC.
• CTEXLI was approved in the US for cerebrotendinous xanthomatosis.
• Mirum has a strong cash position of $292.8 million as of December 31, 2024.

Negatives

• Total operating expenses increased to $424.5 million in 2024 from $295.5 million in 2023.
• The company reported a loss from operations of $87.6 million for the year ended December 31, 2024.
• The net loss for the year ended December 31, 2024, was $87.9 million.

Risks

• The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• The company's success depends on the continued commercial success of its approved products.
• Clinical trial results may not be positive, and regulatory approvals may not be obtained for product candidates.
• The company faces risks associated with its business in general and the impact of geopolitical and macroeconomic events.

Future Outlook

Mirum expects continued revenue growth in 2025 with global net product sales of approximately $420 million to $435 million and anticipates positive cash flow. The company also anticipates multiple clinical and regulatory milestones, including the completion of enrollment for the VISTAS study in PSC in the second half of 2025.

Management Comments

• 2024 was another year of significant growth and accomplishments for Mirum and in 2025 we expect this momentum to continue, said Chris Peetz, chief executive officer of Mirum.
• We continue to expand the reach of our three commercial medicines within our patient communities and look forward to another year of strong financial performance.
• On top of this, we are looking forward to multiple upcoming clinical and regulatory milestones, such as PSC where were expecting full enrollment of our VISTAS trial in the second half of the year.

Industry Context

Mirum's focus on rare liver diseases positions it in a niche market with limited competition, allowing for strong pricing power and market penetration. The company's expansion into new indications and geographies further strengthens its competitive advantage. The approval of CTEXLI and the progress of volixibat in clinical trials demonstrate Mirum's commitment to innovation and addressing unmet medical needs in the rare disease space.

Comparison to Industry Standards

• Compared to companies like Albireo Pharma (now Ipsen) which also focuses on rare liver diseases, Mirum's revenue growth and pipeline progress are competitive.
• Albireo Pharma's Bylvay (odevixibat) is a direct competitor to LIVMARLI, and the market share and growth rates of both drugs are key indicators of their relative success.
• Companies like Intercept Pharmaceuticals (now Alfasigma) with Ocaliva for PBC provide a benchmark for the potential of volixibat in the PBC market.
• The success of orphan drug companies like Vertex Pharmaceuticals in cystic fibrosis highlights the potential for Mirum to dominate its niche market.

Stakeholder Impact

• Shareholders can expect continued growth and potential for increased value.
• Employees can anticipate job security and opportunities for advancement.
• Patients will benefit from the development and availability of new treatments for rare diseases.
• Suppliers and creditors can expect continued business and timely payments.

Next Steps

• Complete enrollment in the VISTAS study of volixibat in PSC in the second half of 2025.
• Initiate a Phase 2 study for MRM-3379 in Fragile X Syndrome (FXS) in 2025.
• Complete enrollment in the VANTAGE study of volixibat in PBC in 2026.
• Complete enrollment in the LIVMARLI EXPAND Phase 3 study for pruritus in rare cholestatic conditions in 2026.
• Continue to expand the commercial reach of LIVMARLI globally.

Key Dates